[1] 中华医学会心血管病学分会.冠状动脉微血管疾病诊断和治疗中国专家共识(2023版)[J].中华心血管病杂志,2024,52(5):460-492. Chinese Society of Cardiology.Chinese medical association.chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases(2023 Edition)[J].Chin J Cardiol,2024,52(5):460-492. [2] SARA J D,WIDMER R J,MATSUZAWA Y,et al.Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease[J].JACC Cardiovasc Interv,2015,8(11):1445-1453. [3] WAYNE N,SINGAMNENI V S,VENKATESH R,et al.Genetic insights into coronary microvascular disease[J].Microcirculation,2025,32(1):e12896. [4] ZHAO Y,CHEN W,WANG D,et al.Role of ferroptosis in coronary microvascular dysfunction and its therapeutic prospects[J].Cardiovascular Research,2023,129(2),349-360. [5] 姜海兵,杨毅,翟雪芹,等.芪红散对巨噬细胞分化及炎症水平的影响[J].新疆医科大学学报,2024,47(7):1019-1023. JIANG H B,Yang Y,ZHAI X Q,et al.Efficacy of QihongSan on macrophage differentiation and inflammation levels[J].J Xinjiang Med Univ,2024,47(7):1019-1023. [6] 姜海兵,翟雪芹,陈战西,等.芪红散联合尼可地尔治疗冠状动脉慢血流随机对照研究[J].中国中西医结合杂志,2021,41(10):1174-1178. JIANG H B,ZHAI X Q,CHEN Z X,et al.Effectiveness of Qihong powder combined with nicorandil on coronary slow flow:a randomized controlled Trial[J].CJITWM,2021,41(10):1174-1178. [7] 智慧敏,李沅萍,高奋.血管内皮细胞铁死亡在动脉粥样硬化中的研究进展[J].医学分子生物学杂志,2025,22(03):295-299,304. ZHI H M,LI Y P,GAO F,et al.Research Progress of ferroptosis of vascular endothelial cells in atherosclerosis[J].J Med Mol Biol,2025,22(03):295-299,304. [8] 徐叔云.药理实验方法学[M].3版.北京:人民卫生出版社,2002:1861-1863. XU S Y.Methodology of Pharmacological Experiment[M].3 rd ed.Beijing:People’s Medical Publishing House,2002:1861-1863. [9] 苏立硕,王贤良,毛静远.冠状动脉微循环障碍动物模型建立的方法及评析[J].中国医学科学院学报,2014,36(05):542-545. SU L S,WANG X L,MAO J Y.Establishment and evaluation on the animal models with coronary microcirculation dysfunction[J].Acta Acad Med Cin,2014,36(05):542-545. [10] 黄克,左可可,顾宁.冠状动脉微血管疾病实验动物模型的研究进展[J].中国实验动物学报,2025,33(11):1648-1662. HUANG K,ZUO K K,GU N,Research progress in experimental animal models of coronary microvascular disease[J].Acta Laboratorium Animalis Scientia Sinica,2025,33(11):1648-1662. [11] 张杭,郭航远.冠状动脉微循环障碍的发病机制及诊治现状[J].临床医学研究与实践,2024,9(06):190-193. ZHANG H,GUO H Y,Pathogenesis and current status of diagnosis and treatment of coronary microvascular dysfunction[J].Clin Med Res Pract,2024,9(06):190-193. [12] 李世军,李泽楠.微血管性心绞痛的病理生理机制与诊疗策略进展[J].中华老年心脑血管病杂志,2024,26(06):715-717. LI S J,LI Z N.Advances in pathophysiological mechanisms and diagnosis-treatment strategies for microvascular angina[J].Chin J Geriatr Heart Brain Vessel Dis,2024,26(06):715-717. [13] WU T,LI Z,WEI Y.Advances in understanding mechanisms underlying mitochondrial structure and function damage by ozone[J].Sci Total Environ,2023,861:160589. [14] WANG Y G,YU X J,QU Y K,et al.Ferrostatin-1 inhibits toll-like receptor 4/NF-κB signaling to alleviate intervertebral disc degeneration in rats[J].Am J Pathol,2023,193(4):430-441. [15] 刘鑫,李茂新,闫丙健,等.基于TLR4/NF-κB通路探究NLRP3对铜绿假单胞菌的清除机制[J].医学分子生物学杂志,2024,21(01):32-38. LIU X,LI M X,YAN B J,et al.Clearance mechanism of NLRP3 against pseudomonas aeruginosa via TLR4/NF-κB pathway[J].J Med Mol Biol,2024,21(01):32-38. [16] XU Z,LIU Y,MA R,et al.Thermosensitive hydrogel incorporating Prussian blue nanoparticles promotes diabetic wound healingviaROS scavenging and mitochondrial function restoration[J].ACS Appl Mater Interfaces,2022,14(12):14059-14071. [17] XU S,WU B,ZHONG B,et al.Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2(Nrf2)/System xc-/ glutathione peroxidase 4(GPX4)axis to inhibit ferroptosis[J].Bioengineered,2021,12(2):10924-10934. |